INO (Inovio Pharmaceuticals) Insider Ownership : 17.45 % (As of Dec. 14, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Inovio Pharmaceuticals's insider ownership is 17.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Inovio Pharmaceuticals's Institutional Ownership is 39.81%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Inovio Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.32%.

Inovio Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Inovio Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Insider Ownership Chart

Inovio Pharmaceuticals Historical Data

The historical data trend for Inovio Pharmaceuticals can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Insider Ownership	21.55	20.98	18.93	17.56	17.58	17.58	17.54	17.54	17.54	17.45

Inovio Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Inovio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

INO:Mexico 0A43:UK GBM:Germany GBM:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Executives

Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
David B. Weiner	director	717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner	officer: Chief Medical Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau	officer: Chief Scientific Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea	officer: Chief Operating Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies	officer: CFO
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim	director, officer: Chief Executive Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard	director	15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno	director
Morton Collins	director
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai	officer: Chief Operating Officer	VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422